Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer’s Disease - 21/11/24
, A. Ezzati 1, R.B. Lipton 1, B.A. Gordon 2, J. Hassenstab 2, J.C. Morris 2, E. Grober 1
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Objective |
To investigate cerebrospinal fluid (CSF) and neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) based on Free and Cued Selective Reminding Test (FCSRT) performance, and to evaluate the effect of APOE ε4 status on this relationship.
Methods |
Data from 586 cognitively unimpaired individuals who had FCSRT, CSF, and volumetric magnetic resonance imaging (MRI) measures available was used. We compared CSF measures of β-amyloid (Aβ42/Aβ40 ratio), phosphorylated tau (p-Tau181), total tau (t-Tau), hippocampal volume, and PIB-PET mean cortical binding potential with partial volume correction (MCBP) among SOMI groups in the whole sample and in subsamples stratified by APOE ε4 status.
Results |
Participants had a mean age of 67.4 (SD=9.1) years, had 16.1 (SD=2.6) years of education, 57.0% were female, and 33.8% were APOE ε4 positive. In the entire sample, there was no significant difference between SOMI stages in Aβ42/Aβ40 ratio, p-Tau181, t-Tau, or PIB-PET MCBP when adjusted for age, sex, and education. However, higher SOMI stages had smaller hippocampal volume (F=3.29, p=0.020). In the stratified sample based on APOE ε4 status, in APOE ε4 positive individuals, higher SOMI stages had higher p-Tau181 (F=2.94, p=0.034) higher t-Tau (F=3.41, p=0.019), and smaller hippocampal volume (F=5.78, p<0.001). There were no significant differences in CSF or imaging biomarkers between SOMI groups in the APOE ε4 negative subsample.
Conclusion |
Cognitively normal older individuals with higher SOMI stages have higher in-vivo tau and neurodegenerative pathology only in APOE ε4 carriers. These original results indicate the potential usefulness of the SOMI staging system in assessing of tau and neurodegenerative pathology.
El texto completo de este artículo está disponible en PDF.Key words : APOE e4, cerebrospinal fluid, cognition, SOMI, biomarkers
Esquema
| Disclosures: K.K.P. has no disclosures. A.E. serves as consultant, advisory board member, or has received honoraria from: Eisai, PCORI Health Care Horizon Scanning System, BioDelivery Sciences International, Inc, and is the owner of Neurodiction, LLC. R.B.L. receives research support from the following sources unrelated to this manuscript: 5U10 NS077308 (PI), R21 AG056920 (Investigator), 1RF1 AG057531 (Site PI), RF1 AG054548 (Investigator), 1RO1 AG048642 (Investigator), R56 AG057548 (Investigator), U01062370 (Investigator), RO1 AG060933 (Investigator), RO1 AG062622 (Investigator), 1UG3FD006795 (mPI), 1U24NS113847 (Investigator). He holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: Abbvie (Allergan), American Academy of Neurology, American Headache Society, Amgen, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s (Promius), Electrocore, Eli Lilly, eNeura Therapeutics, Equinox, GlaxoSmithKline, Grifols, Lundbeck (Alder), Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff’s Headache 7th and 8th Edition, Oxford Press University, 2009, Wiley and Informa. B.A.G has no disclosures. J.H. has no disclosures. J.C.M. and his family do not own stock or have equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. E.G. receives a small royalty for commercial use of the Free and Cued Selective Reminding Test with Immediate Recall (FCSRT+IR). The test is available at no cost to researchers and clinicians. The Albert Einstein College of Medicines holds the copyright for the test. Inquiries should be addressed to Dr. Benjamin Neymotin (Benjamin.Neymotin@einsteinmed.org) in the Office of Biotechnology and Business Development. |
Vol 10 - N° 1
P. 112-119 - janvier 2023 Regresar al número
Artículo precedente
- Age- and Sex-Different Associations between Cognitive Performance and Inflammatory Biomarkers in Community Dwelling Older Adults: towards Precision Preventive Strategies
- B.-A. Chen, W.-J. Lee, C.-P. Chung, L.-N. Peng, Liang-Kung Chen
- Systematic and Comparative Analysis of the Burden of Alzheimer’s Disease and Other Dementias in Mexico. Results at the National and Subnational Levels, 1990–2019
- M. Agudelo-Botero, L. Giraldo-Rodríguez, Mario E. Rojas-Russell
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.